Processa Acquires Vidya, Secures $200M Private Placement
Processa Pharmaceuticals announced the acquisition of Vidya Therapeutics, bringing Vidya's lead asset, VT-7208, a next-generation BTK inhibitor, into its pipeline. Concurrently, Processa secured an oversubscribed private placement financing of approximately $200 million from leading healthcare institutional investors. The proceeds are expected to fund operations into the second half of 2029 and through key clinical milestones, including top-line data from Phase 2 proof-of-concept studies for food allergy, chronic spontaneous urticaria, and relapsing multiple sclerosis.
Key Highlights
- Processa acquired Vidya Therapeutics, gaining lead asset VT-7208.
- Secured approximately $200 million in concurrent private placement financing.
- Proceeds expected to fund operations into the second half of 2029.
- Funding covers key clinical milestones, including Phase 2 data for VT-7208.
- VT-7208 is a next-generation BTKi for immune-mediated diseases.
- Processa stockholders to own ~0.9% post-transaction on a fully-diluted basis.
- Vidya equity holders to own ~46.0% and private placement investors ~52.6%.
Price Impact
More from PCSA
Processa Pharma Shareholders Approve 200,000 Share Incentive Plan Increase
Processa Pharmaceuticals Schedules 2026 Annual Meeting; Proposes Director Elections, Incentive Plan Update
Processa Pharmaceuticals Q1 Net Loss $(3.38)M; Cash $1.69M